221302-75-6 Usage
Uses
Used in Pharmaceutical Industry:
4-(2',6'-DIMETHYLPHENOXY)PHTHALONITRILE is used as a key intermediate in the synthesis of pharmaceutical compounds for its ability to be modified and incorporated into drug molecules, potentially enhancing their therapeutic properties and efficacy.
Used in Polymer Industry:
In the polymer industry, 4-(2',6'-DIMETHYLPHENOXY)PHTHALONITRILE is used as a monomer or building block for the development of new polymeric materials, leveraging its structural features to create polymers with improved properties such as strength, flexibility, or chemical resistance.
Used in Materials Science:
4-(2',6'-DIMETHYLPHENOXY)PHTHALONITRILE is utilized in materials science as a component in the fabrication of advanced materials, taking advantage of its chemical reactivity and structural attributes to engineer materials with novel characteristics for specific applications.
Used in Research and Development:
In research and development, 4-(2',6'-DIMETHYLPHENOXY)PHTHALONITRILE serves as a versatile compound for experimentation and innovation, being modified to suit specific applications or to understand its behavior under various conditions, thus contributing to the advancement of scientific knowledge and technology.
Check Digit Verification of cas no
The CAS Registry Mumber 221302-75-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,1,3,0 and 2 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 221302-75:
(8*2)+(7*2)+(6*1)+(5*3)+(4*0)+(3*2)+(2*7)+(1*5)=76
76 % 10 = 6
So 221302-75-6 is a valid CAS Registry Number.
InChI:InChI=1/C16H12N2O/c1-11-4-3-5-12(2)16(11)19-15-7-6-13(9-17)14(8-15)10-18/h3-8H,1-2H3
221302-75-6Relevant academic research and scientific papers
CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF
-
Page/Page column 58, (2008/06/13)
The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure: Formula (I).
